16.68
+6.24%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Scribe Therapeutics Inc. Common Stock
Its shares trade under the ticker SCTX. It has been listed since 24 July 2026. In the fiscal year to 31 December 2025, it reported revenue of $51.2m and a net loss of $21.8m. At that date it held total assets of $78.2m and shareholders' equity of −$143.4m.
Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing. The company was incorporated in 2017 and is headquartered in Alameda, California.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Listed since
- 24 Jul 2026
- Website
- scribetx.com ↗
- Head office
- 1150 MARINA VILLAGE PKWY, ALAMEDA, CA, 94501
- Incorporated in
- DE
- Classification
- Biological Products, (No Diagnostic Substances)
- Filer status
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Scribe Therapeutics Inc. focuses on CRISPR-based genetic medicines targeting cardiometabolic diseases in the US market.
- STX-1150 offers a single-course in vivo epigenetic silencing treatment for PCSK9 gene targeting.
- ELXR platform enables precise epigenetic silencing without altering DNA sequences for durable treatments.
Weaknesses
- Scribe Therapeutics Inc. operates as a clinical-stage biotechnology company with no approved products yet.
- The company's focus on cardiometabolic conditions limits its market scope to a specific health segment.
- STX-1200 and STX-1400 are still in development without confirmed clinical outcomes.
Opportunities
- US market expansion for CRISPR-based treatments targeting cardiometabolic conditions like PCSK9 and Lp(a).
- ELXR platform could enable new epigenetic therapies beyond current cardiometabolic applications.
- Xe platform supports efficient gene editing for potential new therapeutic applications in the US.
Threats
- Competition from other biotech firms developing CRISPR-based therapies in the US market.
- Regulatory hurdles for clinical-stage biotechnology companies seeking FDA approval.
- High development costs for CRISPR-based genetic medicines in the US healthcare sector.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.